Comparative study on the efficacy of ritipenem acoxil and cefotiam hexetil in chronic lower respiratory tract infections by the double-blind method

Atsushi Saito; Akira Saito; Yoshikazu Kawakami; Etsuro Yamaguchi; Hiroyuki Koba; Shosaku Abe; Mitsuhide Ohmichi; Yohmei Hiraga; Kenjiro Kikuchi; Yoshinobu Ohsaki; Hiroyuki Matsumoto; Hiroshi Inoue; Masami Yoshida; Takashi Mouri; Hitoshi Kobayashi; Takashi Ito; Takeshi Bando; Kenichi Takeuchi; Haruto Hirano; Yukio Tanifuji; Yasuo Tanno; Kunio Shirato; Makoto Takahashi; Masahiro Sakamoto; Toshihiro Nukiwa; Akira Watanabe; Kazuo Sato; Toshio Nakamura; Kenji Yanase; Kunio Dote; Mitsunobu Homma; Nobuo Ito; Akira Ohishi; Kiyoshi Fukuda; Atsushi Nakazawa; Masataka Katsu; Hiroyuki Kobayashi; Susumu Sakayori; Hiroshi Miura; Hidehiro Watanabe; Kaoru Shimada; Shinichi Oka; Hirotaka Sugiyama; Takashi Inamatsu; Yasuyuki Sano; Yasuo Arai; Mamoru Otomo; Hideo Kobayashi; Takashige Kuraki; Hiroyuki Tanaka; Harumi Shishido; Shoko Tanoue; Keiko Tsuchihashi; Izumi Hayashi; Masaru Koyama; Koichiro Kudo; Takeshi Koshino; Jun Akiyama; Takao Okubo; Kenji Tani; Hirotada Ikeda; Akira Shoji; Jun Chiba; Shigeru Ono; Atsuro Honda; Kunihiko Ikehara; Shoichiro Irimajiri; Yasuo Matsuoka; Mitsuo Obana; Fumio Matsumoto; Iwao Sakurai; Shigeki Odagiri; Takashi Ogura; Hiroshi Takahashi; Masaaki Arakawa; Koichi Wada; Fumihide Iwata; Yoshinori Shimazu; Hiroyuki Sega; Hiroki Tsukada; Takashi Kawashima; Nobuki Aoki; Yasutoshi Suzuki; Osamu Sekine; Atsuhiko Sato; Kingo Chida; Masatoshi Iwata; Izumi Shichi; Kazumasa Yasuda; Katsutaka Torikai; Kenzo Takagi; Yoshiaki Watanabe; Hiroyuki Taniguchi; Naohiro Yamashita; Isao Usui; Saburo Izumi; Fumiyuki Kuze; Kenji Bando; Shinichiro Ohyama; Hideki Nishiyama; Takakazu Sugita; Sadao Horikawa; Tadamitsu Kishimoto; Yoshiro Tanio; Akinori Ikeda; Masami Ito; Takeshi Okumoto; Seibun Yonezu; Fumio Miki; Kentaro Okawa; Shigenori Nakajima; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Kazuya Higashino; Takashi Nakano; Akio Maebo; Takahiko Yoshimoto; Takashi Sonoda; Shigeo Nomura; Kazuyuki Yamaguchi; Hiroshi Tokumoto; Masakiyo Nakagawa; Masataka Hirabayashi; Naoki Togawa; Masao Yoshida; Yoshitaka Kawai; Rinzo Soejima; Niro Okimoto; Toshiharu Matsushima; Makoto Kimura; Takao Sasaki; Yukio Matsumoto; Michio Yamakido; Shinichi Ishioka; Masao Kuwahara; Nobuhiro Mochizuki; Teruomi Miyazawa; Jitsuro Yanagida; Kenichi Arita; Kazuhiro Daido; Tsuyoshi Ejima; Saburo Sone; Kenji Tani; Satoshi Miki; Yoshiro Sawae; Koji Takaki; Minoru Yoshida; Takamichi Aritomi; Kotaro Oizumi; Yoichiro Ichikawa; Tsuneaki Shiraishi; Masashi Kawahara; Shinzo Kawaguchi; Tomotaka Kawayama; Yoshihiro Sato; Yoshiaki Honda; Tsuneo Ishibashi; Masahiro Takamoto; Akira Kajiki; Yasuko Harada; Hozumi Yamada; Nobumitsu Fujisawa; Masayuki Ando; Moritaka Suga; Toshinori Doi; Katsumasa Tokunaga; Kiyoshi Shima; Shinobu Takenaka; Kohei Hara; Shigeru Kohno; Mitsuo Kaku; Nobuhiro Koga; Yuichi Inoue; Yuko Yamashita; Shingo Sakata; Takeshi Fujii; Kenji Irifune; Kazunori Shimoguchi; Yoshitsugu Miyazaki; Takashi Watanabe; Yoshifumi Soejima; Keizo Matsumoto; Tsuyoshi Nagatake; Tasuku Sakamoto; Misao Tao; Hiroshi Yamashita; Masakazu Takasugi; Moritoshi Akiyama; Mikio Fujishita; Masaru Nasu; Tohru Yamasaki; Yoichiro Goto; Kaoru Nakama; Soichi Inoue; Shigeru Matsukura; Hideo Mashimoto; Hiroshi Mukae; Atsushi Saito; Hiroshi Fukuhara; Masao Tateyama; Tominori Oyakawa; Koichi Deguchi; Mitsuyoshi Nakashima

Comparative study on the efficacy of ritipenem acoxil and cefotiam hexetil in chronic lower respiratory tract infections by the double-blind method

Atsushi Saito, Akira Saito, Yoshikazu Kawakami, Etsuro Yamaguchi, Hiroyuki Koba, Shosaku Abe, Mitsuhide Ohmichi, Yohmei Hiraga, Kenjiro Kikuchi, Yoshinobu Ohsaki, Hiroyuki Matsumoto, Hiroshi Inoue, Masami Yoshida, Takashi Mouri, Hitoshi Kobayashi, Takashi Ito, Takeshi Bando, Kenichi Takeuchi, Haruto Hirano, Yukio TanifujiYasuo Tanno, Kunio Shirato, Makoto Takahashi, Masahiro Sakamoto, Toshihiro Nukiwa, Akira Watanabe, Kazuo Sato, Toshio Nakamura, Kenji Yanase, Kunio Dote, Mitsunobu Homma, Nobuo Ito, Akira Ohishi, Kiyoshi Fukuda, Atsushi Nakazawa, Masataka Katsu, Hiroyuki Kobayashi, Susumu Sakayori, Hiroshi Miura, Hidehiro Watanabe, Kaoru Shimada, Shinichi Oka, Hirotaka Sugiyama, Takashi Inamatsu, Yasuyuki Sano, Yasuo Arai, Mamoru Otomo, Hideo Kobayashi, Takashige Kuraki, Hiroyuki Tanaka, Harumi Shishido, Shoko Tanoue, Keiko Tsuchihashi, Izumi Hayashi, Masaru Koyama, Koichiro Kudo, Takeshi Koshino, Jun Akiyama, Takao Okubo, Kenji Tani, Hirotada Ikeda, Akira Shoji, Jun Chiba, Shigeru Ono, Atsuro Honda, Kunihiko Ikehara, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Fumio Matsumoto, Iwao Sakurai, Shigeki Odagiri, Takashi Ogura, Hiroshi Takahashi, Masaaki Arakawa, Koichi Wada, Fumihide Iwata, Yoshinori Shimazu, Hiroyuki Sega, Hiroki Tsukada, Takashi Kawashima, Nobuki Aoki, Yasutoshi Suzuki, Osamu Sekine, Atsuhiko Sato, Kingo Chida, Masatoshi Iwata, Izumi Shichi, Kazumasa Yasuda, Katsutaka Torikai, Kenzo Takagi, Yoshiaki Watanabe, Hiroyuki Taniguchi, Naohiro Yamashita, Isao Usui, Saburo Izumi, Fumiyuki Kuze, Kenji Bando, Shinichiro Ohyama, Hideki Nishiyama, Takakazu Sugita, Sadao Horikawa, Tadamitsu Kishimoto, Yoshiro Tanio, Akinori Ikeda, Masami Ito, Takeshi Okumoto, Seibun Yonezu, Fumio Miki, Kentaro Okawa, Shigenori Nakajima, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Kazuya Higashino, Takashi Nakano, Akio Maebo, Takahiko Yoshimoto, Takashi Sonoda, Shigeo Nomura, Kazuyuki Yamaguchi, Hiroshi Tokumoto, Masakiyo Nakagawa, Masataka Hirabayashi, Naoki Togawa, Masao Yoshida, Yoshitaka Kawai, Rinzo Soejima, Niro Okimoto, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yukio Matsumoto, Michio Yamakido, Shinichi Ishioka, Masao Kuwahara, Nobuhiro Mochizuki, Teruomi Miyazawa, Jitsuro Yanagida, Kenichi Arita, Kazuhiro Daido, Tsuyoshi Ejima, Saburo Sone, Kenji Tani, Satoshi Miki, Yoshiro Sawae, Koji Takaki, Minoru Yoshida, Takamichi Aritomi, Kotaro Oizumi, Yoichiro Ichikawa, Tsuneaki Shiraishi, Masashi Kawahara, Shinzo Kawaguchi, Tomotaka Kawayama, Yoshihiro Sato, Yoshiaki Honda, Tsuneo Ishibashi, Masahiro Takamoto, Akira Kajiki, Yasuko Harada, Hozumi Yamada, Nobumitsu Fujisawa, Masayuki Ando, Moritaka Suga, Toshinori Doi, Katsumasa Tokunaga, Kiyoshi Shima, Shinobu Takenaka, Kohei Hara, Shigeru Kohno, Mitsuo Kaku, Nobuhiro Koga, Yuichi Inoue, Yuko Yamashita, Shingo Sakata, Takeshi Fujii, Kenji Irifune, Kazunori Shimoguchi, Yoshitsugu Miyazaki, Takashi Watanabe, Yoshifumi Soejima, Keizo Matsumoto, Tsuyoshi Nagatake, Tasuku Sakamoto, Misao Tao, Hiroshi Yamashita, Masakazu Takasugi, Moritoshi Akiyama, Mikio Fujishita, Masaru Nasu, Tohru Yamasaki, Yoichiro Goto, Kaoru Nakama, Soichi Inoue, Shigeru Matsukura, Hideo Mashimoto, Hiroshi Mukae, Atsushi Saito, Hiroshi Fukuhara, Masao Tateyama, Tominori Oyakawa, Koichi Deguchi, Mitsuyoshi Nakashima

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against chronic lower respiratory tract infections, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as a control drug. RIPM-AC was orally administered at 200 mg, and CTM-HE at 400 mg, t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 202, of which 151 cases (RIPM-AC group: 75, CTM-HE group: 76) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent+good) were 85.3% (64/75) in the RIPM-AC group and 80.3% (61/76) in the CTM-HE group. There was no significant difference between the two groups, hence the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 50.0% (13/26) in the RIPM-AC group and 75.0% (18/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 10 cases (11.0%) of the RIPM-AC group and 10 cases (10.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 8 cases(9.5%) of the RIPM-AC group and in 14 cases (16.7%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects and abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 73 cases (80.2%) and CTM-HE in 71 cases (77.2%), with no significant difference. 4. The usefulness rates (markedly useful+useful) were 79.5% (62/78) in the RIPM-AC group and 76.9% (60/78) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of chronic lower respiratory tract infections.

Original language	English
Pages (from-to)	244-249
Number of pages	6
Journal	The Japanese Journal of Antibiotics
Volume	49
Issue number	3
Publication status	Published - 1996 Mar
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Saito, A., Saito, A., Kawakami, Y., Yamaguchi, E., Koba, H., Abe, S., Ohmichi, M., Hiraga, Y., Kikuchi, K., Ohsaki, Y., Matsumoto, H., Inoue, H., Yoshida, M., Mouri, T., Kobayashi, H., Ito, T., Bando, T., Takeuchi, K., Hirano, H., ... Nakashima, M. (1996). Comparative study on the efficacy of ritipenem acoxil and cefotiam hexetil in chronic lower respiratory tract infections by the double-blind method. The Japanese Journal of Antibiotics, 49(3), 244-249.

Saito, A, Saito, A, Kawakami, Y, Yamaguchi, E, Koba, H, Abe, S, Ohmichi, M, Hiraga, Y, Kikuchi, K, Ohsaki, Y, Matsumoto, H, Inoue, H, Yoshida, M, Mouri, T, Kobayashi, H, Ito, T, Bando, T, Takeuchi, K, Hirano, H, Tanifuji, Y, Tanno, Y, Shirato, K, Takahashi, M, Sakamoto, M, Nukiwa, T, Watanabe, A, Sato, K, Nakamura, T, Yanase, K, Dote, K, Homma, M, Ito, N, Ohishi, A, Fukuda, K, Nakazawa, A, Katsu, M, Kobayashi, H, Sakayori, S, Miura, H, Watanabe, H, Shimada, K, Oka, S, Sugiyama, H, Inamatsu, T, Sano, Y, Arai, Y, Otomo, M, Kobayashi, H, Kuraki, T, Tanaka, H, Shishido, H, Tanoue, S, Tsuchihashi, K, Hayashi, I, Koyama, M, Kudo, K, Koshino, T, Akiyama, J, Okubo, T, Tani, K, Ikeda, H, Shoji, A, Chiba, J, Ono, S, Honda, A, Ikehara, K, Irimajiri, S, Matsuoka, Y, Obana, M, Matsumoto, F, Sakurai, I, Odagiri, S, Ogura, T, Takahashi, H, Arakawa, M, Wada, K, Iwata, F, Shimazu, Y, Sega, H, Tsukada, H, Kawashima, T, Aoki, N, Suzuki, Y, Sekine, O, Sato, A, Chida, K, Iwata, M, Shichi, I, Yasuda, K, Torikai, K, Takagi, K, Watanabe, Y, Taniguchi, H, Yamashita, N, Usui, I, Izumi, S, Kuze, F, Bando, K, Ohyama, S, Nishiyama, H, Sugita, T, Horikawa, S, Kishimoto, T, Tanio, Y, Ikeda, A, Ito, M, Okumoto, T, Yonezu, S, Miki, F, Okawa, K, Nakajima, S, Narita, N, Sawaki, M, Mikasa, K, Higashino, K, Nakano, T, Maebo, A, Yoshimoto, T, Sonoda, T, Nomura, S, Yamaguchi, K, Tokumoto, H, Nakagawa, M, Hirabayashi, M, Togawa, N, Yoshida, M, Kawai, Y, Soejima, R, Okimoto, N, Matsushima, T, Kimura, M, Sasaki, T, Matsumoto, Y, Yamakido, M, Ishioka, S, Kuwahara, M, Mochizuki, N, Miyazawa, T, Yanagida, J, Arita, K, Daido, K, Ejima, T, Sone, S, Tani, K, Miki, S, Sawae, Y, Takaki, K, Yoshida, M, Aritomi, T, Oizumi, K, Ichikawa, Y, Shiraishi, T, Kawahara, M, Kawaguchi, S, Kawayama, T, Sato, Y, Honda, Y, Ishibashi, T, Takamoto, M, Kajiki, A, Harada, Y, Yamada, H, Fujisawa, N, Ando, M, Suga, M, Doi, T, Tokunaga, K, Shima, K, Takenaka, S, Hara, K, Kohno, S, Kaku, M, Koga, N, Inoue, Y, Yamashita, Y, Sakata, S, Fujii, T, Irifune, K, Shimoguchi, K, Miyazaki, Y, Watanabe, T, Soejima, Y, Matsumoto, K, Nagatake, T, Sakamoto, T, Tao, M, Yamashita, H, Takasugi, M, Akiyama, M, Fujishita, M, Nasu, M, Yamasaki, T, Goto, Y, Nakama, K, Inoue, S, Matsukura, S, Mashimoto, H, Mukae, H, Saito, A, Fukuhara, H, Tateyama, M, Oyakawa, T, Deguchi, K & Nakashima, M 1996, 'Comparative study on the efficacy of ritipenem acoxil and cefotiam hexetil in chronic lower respiratory tract infections by the double-blind method', The Japanese Journal of Antibiotics, vol. 49, no. 3, pp. 244-249.

@article{0e637e64a38b4680a48ae020ec0ea18f,

title = "Comparative study on the efficacy of ritipenem acoxil and cefotiam hexetil in chronic lower respiratory tract infections by the double-blind method",

abstract = "To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against chronic lower respiratory tract infections, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as a control drug. RIPM-AC was orally administered at 200 mg, and CTM-HE at 400 mg, t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 202, of which 151 cases (RIPM-AC group: 75, CTM-HE group: 76) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent+good) were 85.3% (64/75) in the RIPM-AC group and 80.3% (61/76) in the CTM-HE group. There was no significant difference between the two groups, hence the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 50.0% (13/26) in the RIPM-AC group and 75.0% (18/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 10 cases (11.0%) of the RIPM-AC group and 10 cases (10.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 8 cases(9.5%) of the RIPM-AC group and in 14 cases (16.7%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects and abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 73 cases (80.2%) and CTM-HE in 71 cases (77.2%), with no significant difference. 4. The usefulness rates (markedly useful+useful) were 79.5% (62/78) in the RIPM-AC group and 76.9% (60/78) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of chronic lower respiratory tract infections.",

author = "Atsushi Saito and Akira Saito and Yoshikazu Kawakami and Etsuro Yamaguchi and Hiroyuki Koba and Shosaku Abe and Mitsuhide Ohmichi and Yohmei Hiraga and Kenjiro Kikuchi and Yoshinobu Ohsaki and Hiroyuki Matsumoto and Hiroshi Inoue and Masami Yoshida and Takashi Mouri and Hitoshi Kobayashi and Takashi Ito and Takeshi Bando and Kenichi Takeuchi and Haruto Hirano and Yukio Tanifuji and Yasuo Tanno and Kunio Shirato and Makoto Takahashi and Masahiro Sakamoto and Toshihiro Nukiwa and Akira Watanabe and Kazuo Sato and Toshio Nakamura and Kenji Yanase and Kunio Dote and Mitsunobu Homma and Nobuo Ito and Akira Ohishi and Kiyoshi Fukuda and Atsushi Nakazawa and Masataka Katsu and Hiroyuki Kobayashi and Susumu Sakayori and Hiroshi Miura and Hidehiro Watanabe and Kaoru Shimada and Shinichi Oka and Hirotaka Sugiyama and Takashi Inamatsu and Yasuyuki Sano and Yasuo Arai and Mamoru Otomo and Hideo Kobayashi and Takashige Kuraki and Hiroyuki Tanaka and Harumi Shishido and Shoko Tanoue and Keiko Tsuchihashi and Izumi Hayashi and Masaru Koyama and Koichiro Kudo and Takeshi Koshino and Jun Akiyama and Takao Okubo and Kenji Tani and Hirotada Ikeda and Akira Shoji and Jun Chiba and Shigeru Ono and Atsuro Honda and Kunihiko Ikehara and Shoichiro Irimajiri and Yasuo Matsuoka and Mitsuo Obana and Fumio Matsumoto and Iwao Sakurai and Shigeki Odagiri and Takashi Ogura and Hiroshi Takahashi and Masaaki Arakawa and Koichi Wada and Fumihide Iwata and Yoshinori Shimazu and Hiroyuki Sega and Hiroki Tsukada and Takashi Kawashima and Nobuki Aoki and Yasutoshi Suzuki and Osamu Sekine and Atsuhiko Sato and Kingo Chida and Masatoshi Iwata and Izumi Shichi and Kazumasa Yasuda and Katsutaka Torikai and Kenzo Takagi and Yoshiaki Watanabe and Hiroyuki Taniguchi and Naohiro Yamashita and Isao Usui and Saburo Izumi and Fumiyuki Kuze and Kenji Bando and Shinichiro Ohyama and Hideki Nishiyama and Takakazu Sugita and Sadao Horikawa and Tadamitsu Kishimoto and Yoshiro Tanio and Akinori Ikeda and Masami Ito and Takeshi Okumoto and Seibun Yonezu and Fumio Miki and Kentaro Okawa and Shigenori Nakajima and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Kazuya Higashino and Takashi Nakano and Akio Maebo and Takahiko Yoshimoto and Takashi Sonoda and Shigeo Nomura and Kazuyuki Yamaguchi and Hiroshi Tokumoto and Masakiyo Nakagawa and Masataka Hirabayashi and Naoki Togawa and Masao Yoshida and Yoshitaka Kawai and Rinzo Soejima and Niro Okimoto and Toshiharu Matsushima and Makoto Kimura and Takao Sasaki and Yukio Matsumoto and Michio Yamakido and Shinichi Ishioka and Masao Kuwahara and Nobuhiro Mochizuki and Teruomi Miyazawa and Jitsuro Yanagida and Kenichi Arita and Kazuhiro Daido and Tsuyoshi Ejima and Saburo Sone and Kenji Tani and Satoshi Miki and Yoshiro Sawae and Koji Takaki and Minoru Yoshida and Takamichi Aritomi and Kotaro Oizumi and Yoichiro Ichikawa and Tsuneaki Shiraishi and Masashi Kawahara and Shinzo Kawaguchi and Tomotaka Kawayama and Yoshihiro Sato and Yoshiaki Honda and Tsuneo Ishibashi and Masahiro Takamoto and Akira Kajiki and Yasuko Harada and Hozumi Yamada and Nobumitsu Fujisawa and Masayuki Ando and Moritaka Suga and Toshinori Doi and Katsumasa Tokunaga and Kiyoshi Shima and Shinobu Takenaka and Kohei Hara and Shigeru Kohno and Mitsuo Kaku and Nobuhiro Koga and Yuichi Inoue and Yuko Yamashita and Shingo Sakata and Takeshi Fujii and Kenji Irifune and Kazunori Shimoguchi and Yoshitsugu Miyazaki and Takashi Watanabe and Yoshifumi Soejima and Keizo Matsumoto and Tsuyoshi Nagatake and Tasuku Sakamoto and Misao Tao and Hiroshi Yamashita and Masakazu Takasugi and Moritoshi Akiyama and Mikio Fujishita and Masaru Nasu and Tohru Yamasaki and Yoichiro Goto and Kaoru Nakama and Soichi Inoue and Shigeru Matsukura and Hideo Mashimoto and Hiroshi Mukae and Atsushi Saito and Hiroshi Fukuhara and Masao Tateyama and Tominori Oyakawa and Koichi Deguchi and Mitsuyoshi Nakashima",

year = "1996",

month = mar,

language = "English",

volume = "49",

pages = "244--249",

journal = "The Japanese Journal of Antibiotics",

issn = "0368-2781",

number = "3",

}

TY - JOUR

T1 - Comparative study on the efficacy of ritipenem acoxil and cefotiam hexetil in chronic lower respiratory tract infections by the double-blind method

AU - Saito, Atsushi

AU - Saito, Akira

AU - Kawakami, Yoshikazu

AU - Yamaguchi, Etsuro

AU - Koba, Hiroyuki

AU - Abe, Shosaku

AU - Ohmichi, Mitsuhide

AU - Hiraga, Yohmei

AU - Kikuchi, Kenjiro

AU - Ohsaki, Yoshinobu

AU - Matsumoto, Hiroyuki

AU - Inoue, Hiroshi

AU - Yoshida, Masami

AU - Mouri, Takashi

AU - Kobayashi, Hitoshi

AU - Ito, Takashi

AU - Bando, Takeshi

AU - Takeuchi, Kenichi

AU - Hirano, Haruto

AU - Tanifuji, Yukio

AU - Tanno, Yasuo

AU - Shirato, Kunio

AU - Takahashi, Makoto

AU - Sakamoto, Masahiro

AU - Nukiwa, Toshihiro

AU - Watanabe, Akira

AU - Sato, Kazuo

AU - Nakamura, Toshio

AU - Yanase, Kenji

AU - Dote, Kunio

AU - Homma, Mitsunobu

AU - Ito, Nobuo

AU - Ohishi, Akira

AU - Fukuda, Kiyoshi

AU - Nakazawa, Atsushi

AU - Katsu, Masataka

AU - Kobayashi, Hiroyuki

AU - Sakayori, Susumu

AU - Miura, Hiroshi

AU - Watanabe, Hidehiro

AU - Shimada, Kaoru

AU - Oka, Shinichi

AU - Sugiyama, Hirotaka

AU - Inamatsu, Takashi

AU - Sano, Yasuyuki

AU - Arai, Yasuo

AU - Otomo, Mamoru

AU - Kobayashi, Hideo

AU - Kuraki, Takashige

AU - Tanaka, Hiroyuki

AU - Shishido, Harumi

AU - Tanoue, Shoko

AU - Tsuchihashi, Keiko

AU - Hayashi, Izumi

AU - Koyama, Masaru

AU - Kudo, Koichiro

AU - Koshino, Takeshi

AU - Akiyama, Jun

AU - Okubo, Takao

AU - Tani, Kenji

AU - Ikeda, Hirotada

AU - Shoji, Akira

AU - Chiba, Jun

AU - Ono, Shigeru

AU - Honda, Atsuro

AU - Ikehara, Kunihiko

AU - Irimajiri, Shoichiro

AU - Matsuoka, Yasuo

AU - Obana, Mitsuo

AU - Matsumoto, Fumio

AU - Sakurai, Iwao

AU - Odagiri, Shigeki

AU - Ogura, Takashi

AU - Takahashi, Hiroshi

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Iwata, Fumihide

AU - Shimazu, Yoshinori

AU - Sega, Hiroyuki

AU - Tsukada, Hiroki

AU - Kawashima, Takashi

AU - Aoki, Nobuki

AU - Suzuki, Yasutoshi

AU - Sekine, Osamu

AU - Sato, Atsuhiko

AU - Chida, Kingo

AU - Iwata, Masatoshi

AU - Shichi, Izumi

AU - Yasuda, Kazumasa

AU - Torikai, Katsutaka

AU - Takagi, Kenzo

AU - Watanabe, Yoshiaki

AU - Taniguchi, Hiroyuki

AU - Yamashita, Naohiro

AU - Usui, Isao

AU - Izumi, Saburo

AU - Kuze, Fumiyuki

AU - Bando, Kenji

AU - Ohyama, Shinichiro

AU - Nishiyama, Hideki

AU - Sugita, Takakazu

AU - Horikawa, Sadao

AU - Kishimoto, Tadamitsu

AU - Tanio, Yoshiro

AU - Ikeda, Akinori

AU - Ito, Masami

AU - Okumoto, Takeshi

AU - Yonezu, Seibun

AU - Miki, Fumio

AU - Okawa, Kentaro

AU - Nakajima, Shigenori

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Higashino, Kazuya

AU - Nakano, Takashi

AU - Maebo, Akio

AU - Yoshimoto, Takahiko

AU - Sonoda, Takashi

AU - Nomura, Shigeo

AU - Yamaguchi, Kazuyuki

AU - Tokumoto, Hiroshi

AU - Nakagawa, Masakiyo

AU - Hirabayashi, Masataka

AU - Togawa, Naoki

AU - Yoshida, Masao

AU - Kawai, Yoshitaka

AU - Soejima, Rinzo

AU - Okimoto, Niro

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Sasaki, Takao

AU - Matsumoto, Yukio

AU - Yamakido, Michio

AU - Ishioka, Shinichi

AU - Kuwahara, Masao

AU - Mochizuki, Nobuhiro

AU - Miyazawa, Teruomi

AU - Yanagida, Jitsuro

AU - Arita, Kenichi

AU - Daido, Kazuhiro

AU - Ejima, Tsuyoshi

AU - Sone, Saburo

AU - Tani, Kenji

AU - Miki, Satoshi

AU - Sawae, Yoshiro

AU - Takaki, Koji

AU - Yoshida, Minoru

AU - Aritomi, Takamichi

AU - Oizumi, Kotaro

AU - Ichikawa, Yoichiro

AU - Shiraishi, Tsuneaki

AU - Kawahara, Masashi

AU - Kawaguchi, Shinzo

AU - Kawayama, Tomotaka

AU - Sato, Yoshihiro

AU - Honda, Yoshiaki

AU - Ishibashi, Tsuneo

AU - Takamoto, Masahiro

AU - Kajiki, Akira

AU - Harada, Yasuko

AU - Yamada, Hozumi

AU - Fujisawa, Nobumitsu

AU - Ando, Masayuki

AU - Suga, Moritaka

AU - Doi, Toshinori

AU - Tokunaga, Katsumasa

AU - Shima, Kiyoshi

AU - Takenaka, Shinobu

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Kaku, Mitsuo

AU - Koga, Nobuhiro

AU - Inoue, Yuichi

AU - Yamashita, Yuko

AU - Sakata, Shingo

AU - Fujii, Takeshi

AU - Irifune, Kenji

AU - Shimoguchi, Kazunori

AU - Miyazaki, Yoshitsugu

AU - Watanabe, Takashi

AU - Soejima, Yoshifumi

AU - Matsumoto, Keizo

AU - Nagatake, Tsuyoshi

AU - Sakamoto, Tasuku

AU - Tao, Misao

AU - Yamashita, Hiroshi

AU - Takasugi, Masakazu

AU - Akiyama, Moritoshi

AU - Fujishita, Mikio

AU - Nasu, Masaru

AU - Yamasaki, Tohru

AU - Goto, Yoichiro

AU - Nakama, Kaoru

AU - Inoue, Soichi

AU - Matsukura, Shigeru

AU - Mashimoto, Hideo

AU - Mukae, Hiroshi

AU - Saito, Atsushi

AU - Fukuhara, Hiroshi

AU - Tateyama, Masao

AU - Oyakawa, Tominori

AU - Deguchi, Koichi

AU - Nakashima, Mitsuyoshi

PY - 1996/3

Y1 - 1996/3

N2 - To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against chronic lower respiratory tract infections, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as a control drug. RIPM-AC was orally administered at 200 mg, and CTM-HE at 400 mg, t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 202, of which 151 cases (RIPM-AC group: 75, CTM-HE group: 76) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent+good) were 85.3% (64/75) in the RIPM-AC group and 80.3% (61/76) in the CTM-HE group. There was no significant difference between the two groups, hence the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 50.0% (13/26) in the RIPM-AC group and 75.0% (18/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 10 cases (11.0%) of the RIPM-AC group and 10 cases (10.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 8 cases(9.5%) of the RIPM-AC group and in 14 cases (16.7%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects and abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 73 cases (80.2%) and CTM-HE in 71 cases (77.2%), with no significant difference. 4. The usefulness rates (markedly useful+useful) were 79.5% (62/78) in the RIPM-AC group and 76.9% (60/78) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of chronic lower respiratory tract infections.

AB - To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against chronic lower respiratory tract infections, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as a control drug. RIPM-AC was orally administered at 200 mg, and CTM-HE at 400 mg, t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 202, of which 151 cases (RIPM-AC group: 75, CTM-HE group: 76) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent+good) were 85.3% (64/75) in the RIPM-AC group and 80.3% (61/76) in the CTM-HE group. There was no significant difference between the two groups, hence the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 50.0% (13/26) in the RIPM-AC group and 75.0% (18/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 10 cases (11.0%) of the RIPM-AC group and 10 cases (10.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 8 cases(9.5%) of the RIPM-AC group and in 14 cases (16.7%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects and abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 73 cases (80.2%) and CTM-HE in 71 cases (77.2%), with no significant difference. 4. The usefulness rates (markedly useful+useful) were 79.5% (62/78) in the RIPM-AC group and 76.9% (60/78) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of chronic lower respiratory tract infections.

UR - http://www.scopus.com/inward/record.url?scp=9244248583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244248583&partnerID=8YFLogxK

M3 - Review article

C2 - 8935119

AN - SCOPUS:9244248583

SN - 0368-2781

VL - 49

SP - 244

EP - 249

JO - The Japanese Journal of Antibiotics

JF - The Japanese Journal of Antibiotics

IS - 3

ER -

Comparative study on the efficacy of ritipenem acoxil and cefotiam hexetil in chronic lower respiratory tract infections by the double-blind method

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this